Please wait
N/A0001861795EX-FILING FEES000186179522025-02-272025-02-27000186179512025-02-272025-02-2700018617952025-02-272025-02-27xbrli:purexbrli:sharesutr:Aiso4217:USD

Exhibit 107

Calculation of Filing Fee Table

Form S-8

(Form Type)

Definitive Healthcare Corp.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Security

Type

Security Class

Title

Fee

Calculation

Rule

Amount

Registered(1)

Proposed

Maximum

Offering Price

Per Unit(2)

Maximum

Aggregate

Offering

Price(2)

Fee Rate

Amount of

Registration

Fee

Equity

 

Class A

common stock,

par value

$0.001 per

share

 

Other

 

5,697,677(3)

 

$4.94

 

$28,146,524.38

 

0.00015310

 

$4,309.23

Equity

 

Class A

common stock,

par value

$0.001 per

share

 

Other

 

2,117,650(4)

 

$4.94

 

$10,461,191.00

 

0.00015310

 

$1,601.61

Total Offering Amounts

$38,607,715.38

$5,910.84

Total Fee Offsets

Net Fee Due

$5,910.84

(1)

Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s Class A common stock, par value $0.001 per share (“Common Stock”), which become issuable under the Registrant’s 2021 Equity Incentive Plan (the “2021 Plan”) and 2023 Inducement Plan (the “2023 Inducement Plan”) by reason of any stock split, stock dividend, recapitalization, or other similar transaction.

(2)

Estimated in accordance with Rule 457(h) and Rule 457(c) of the Securities Act. The price per share and aggregate offering price are based upon the average of the high and low prices of the Registrant’s Common Stock on February 21, 2025, as reported on the Nasdaq Global Select Market.

(3)

Represents the number of additional shares of Common Stock available for issuance as a result of the annual evergreen increase on January 1, 2025, under the 2021 Plan.

 

(4)

Represents the number of additional shares of Common Stock that were reserved for issuance under the 2023 Inducement Plan.